| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
28,395 |
27,962 |
$5.89M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,879 |
11,734 |
$1.71M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
6,103 |
6,103 |
$1.66M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,777 |
4,777 |
$856K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
20,699 |
20,528 |
$805K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,849 |
8,811 |
$257K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
11,715 |
11,656 |
$169K |
| 87807 |
|
3,340 |
3,312 |
$39K |
| 71045 |
Radiologic examination, chest; single view |
575 |
570 |
$22K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
639 |
607 |
$11K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
77 |
77 |
$6K |
| 99051 |
|
296 |
296 |
$2K |
| 81003 |
|
12 |
12 |
$24.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
221 |
220 |
$17.46 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
12 |
12 |
$3.84 |